Brain-computer interfaces sound like science fiction until you realize human trials are already happening. Here’s what Neuralink actually is, what it’s actually achieved so far, and — importantly — the real, accurate picture on investing in it, since a lot of content online gets this part wrong or misleading.
What Neuralink Actually Is
Founded in 2016 by Elon Musk alongside neuroscience and engineering co-founders, Neuralink is developing a brain-machine interface — a chip implanted in the brain that reads neural activity and translates it into digital signals.
The core device is called the N1 chip: wireless, rechargeable, implanted directly into the brain’s cortex. It monitors how neurons fire when you think, move, or process sensory input, then converts that activity into signals a computer can interpret.
What It’s Actually Achieved So Far
Early testing happened in pigs and monkeys — including a widely-shared demo of a monkey playing a simple video game using only its neural signals, no physical controller. Neuralink performed its first human implantation in early 2024, and by late 2025, multiple patients had received the device.
The surgery itself is done by a custom robot called R1, designed for the precision this procedure requires. In human trials, patients have demonstrated the ability to control a computer cursor using thought alone — a genuine milestone, even with real technical hiccups along the way, including reported issues with electrode threads detaching in the earliest trial, which Neuralink says it addressed with a software fix.
Where This Could Realistically Go
Medical applications are the actual near-term focus — restoring some motor function for people with paralysis or ALS, and potentially restoring communication ability or vision in specific conditions. This is genuinely where the technology is being tested and where regulatory approval efforts (FDA “Breakthrough Device” designations) are focused.
The more speculative long-term vision — instant skill downloads, thought-to-thought communication, merging human and artificial intelligence — is Musk’s stated ambition, but it’s genuinely speculative at this stage, not something close to happening. Worth knowing the difference between the medical trials actually underway and the far future vision often discussed alongside them.
Real Concerns Worth Taking Seriously
Data security is a genuine open question. If a device is reading and transmitting neural signals, what happens if that connection is compromised? This isn’t paranoia — it’s a real question researchers and ethicists in this field are actively raising.
Regulatory and safety scrutiny is intensifying, not easing. Neuralink has faced criticism over animal testing practices in its early research phase, and some medical professionals have raised concerns about transparency in its human trial reporting. This is a technology moving fast, and oversight is still catching up.
Competition exists, and it’s relevant. Companies like Synchron are developing less invasive brain-computer interfaces, and established players like Blackrock Neurotech have been in this space for years. Neuralink isn’t operating in a vacuum, despite getting the most media attention due to Musk’s profile.
The Honest Truth About Investing in Neuralink
This is the part most content on this topic gets wrong, so here it is accurately: Neuralink is a private company. Retail investors cannot buy shares directly, period. There’s no public stock ticker, no low-minimum crowdfunding-style access, and no IPO date announced as of 2026.
The only way to gain any exposure is through private secondary markets (like Forge Global or EquityZen), and these require accredited investor status — under US rules, that means a net worth over $1 million (excluding your home) or annual income over $200,000. Minimum investments on these platforms typically start at $10,000-$50,000, not a few thousand dollars.
For readers in Pakistan or India specifically, direct access to Neuralink as an investment simply isn’t realistic or available right now — and that’s true for the vast majority of retail investors globally, not just here. If you see any platform, group, or “investment opportunity” promising low-minimum, easy access to Neuralink shares, treat it with serious skepticism. This is exactly the kind of hype-adjacent territory where scams attach themselves to a famous name.
If you want actual exposure to this sector as an investor: publicly traded companies in the neurotech-adjacent space, or diversified funds that include private “moonshot” holdings (like the ARK Venture Fund, which includes Neuralink as one of many positions), are realistic options for regular investors — though this isn’t financial advice, and you should research thoroughly and consider your own risk tolerance before investing in anything.
Bottom Line
Neuralink represents genuinely significant progress in brain-computer interface medicine, with real human trials happening now, not just concept demos. The near-term applications — restoring mobility and communication for people with severe conditions — are the real story. The far-future vision of thought-to-thought communication is genuinely speculative. And if anyone offers you an “easy way in” to invest in Neuralink directly, that claim doesn’t match how private company investing actually works — treat it as a red flag, not an opportunity.
Some background in this post is informed by a talk from Pakistani researcher Zeeshan Usmani. Watch the original video here.
Disclaimer: This post is for educational purposes only and does not constitute financial advice.